Patients with aplastic anemia can be treated with transplantation, which is usually useful. Allogeneic hematopoietic stem cell transplantation is the treatment of choice for acute severe remittent anemia. Patients can undergo allogeneic stem cell transplantation if they have a suitable match for stem cell transplantation, but because of the abnormal hematopoietic milieu in patients with aplastic anemia, cell transplantation is riskier and more expensive. There is still a possibility that the disease may flare up again after the transplant. However, allogeneic HSCT is the first step in the treatment of patients with acute severe remittent disease. Aplastic anemia is a disease of the blood system caused by abnormalities in one’s own hematopoietic environment and abnormalities in hematopoietic stem cells. Currently, priority is given to the use of drug therapy, such as testosterone undecanoate which can promote the production of its own red blood cells, and immunosuppressants such as cyclophosphamide and cyclosporine, which can inhibit the destruction of normal hematopoietic function by its own inflammatory factors. Patients should receive treatment under the guidance of a physician.